Skip to main content
ARDX logo

Ardelyx, Inc. (ARDX) Stock: Price, Forecast & Analyst Target

Ardelyx, Inc. (ARDX) — MoonshotScore 25/100 (Weak band), calculated Nov 18, 2026. Price $3.06 (-1.92%), as of the Nov 19, 2026 trading session; market cap $769M.

Educational signal · not a buy or sell recommendation · How to read this

$3.06 −$0.06 (-1.92%) Market Cap $769M

Ardelyx, Inc. · ARDX · NASDAQ

Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative treatments for gastrointestinal and cardiorenal diseases. With a strong pipeline including tenapanor, Ardelyx aims to address significant unmet medical needs in the U.S. and international markets.

Price as of Nov 19, 2026

Key Statistics

25 of 100

MoonshotScore v2 · Ardelyx (ARDX)

Weak
Business Quality Solid (74)
Financial Safety Fragile (19)
Valuation Full (58)
Growth Durability Growing (76)
Momentum Slipping (37)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth, but a fragile balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Slipping.

  • quarterly revenue $110M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 0.01 · Piotroski F 2

Holding back: balance-sheet strain

Helping: business quality, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ARDX (57 recorded, newest six shown)
RecordedScoreBand
24Weak
25Weak
25Weak
25Weak
25Weak
25Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$3.06
Change on the day-1.92%
52-week range$2.80 – $8.40
Market capitalisation$769M—
Shares traded on the day3.39M

Price & events

Other perspectives

Council score for Ardelyx (ARDX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Moderate
Momentum Weak

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Ardelyx (ARDX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ardelyx, Inc. (ARDX) is listed on NASDAQ. It employs 489 people and is led by Michael G. Raab. In Q3 FY2025 it reported revenue of $110M and net income of -$969,000. The market values it at $769M.

2 · Latest results

What do the latest results show for Ardelyx (ARDX)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $110M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$110M-$969,000-$0.0040 (diluted)
Q4 FY2025$125M-$407,000-$0.0017 (diluted)
Q1 FY2026$94M-$38M-$0.15 (diluted)
Q2 FY2026$121M-$17M-$0.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ardelyx (ARDX)?

Short answer

The MoonshotScore pillars rate business quality, durable growth as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 0.01 · Piotroski F 2. Trailing ratios: ROE -34.9% · ROA -4.2% · current ratio 3.45.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 0.01 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-34.9%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Ardelyx (ARDX)?

Short answer · as of

Current published price targets run low $13.00 · high $13.00 · consensus $13.00 · median $13.00 against a quoted price of $3.06 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Oct 30, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Ardelyx compare with its peers?

Short answer

Ardelyx's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Innoviva, Inc. (INVA) Same industry, near in market value$18.40 Nov 18, 2026$1.31B96 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Same industry, near in market value$47.40 Nov 19, 2026$1.41B76 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$40.04 Nov 19, 2026$1.30B69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$18.52 Nov 19, 2026$1.14B66 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Alto Neuroscience, Inc. (ANRO) Same industry, near in market value$26.51 Nov 19, 2026$1.06B60 5-pillar Nov 18, 2026
Ardelyx (ARDX) — this page$3.06$769M25

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$13.00 – $13.00
Consensus target
$13.00
Median target
$13.00

Consensus record · Captured .

Measured against a quoted price of $3.06 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 21, 2026

Transactions
46
Identified insiders
15
Purchases
0
Sales
24
Other transactions
22

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ARDX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ARDX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Ardelyx (ARDX)?

Read these with our analysis →

What Investors Ask About Ardelyx (ARDX)

These answers are editorial: 1 of these 9 answers is drawn from the ARDX research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ARDX?

ARDX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative treatments for gastrointestinal and cardiorenal diseases.

Is ARDX a good stock to buy?

Stock Expert AI does not rate ARDX buy, sell or hold. Ardelyx, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ARDX stock price today?

The last price recorded for Ardelyx, Inc. (ARDX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ARDX price target?

The analyst consensus price target for Ardelyx, Inc. (ARDX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for ARDX?

Ardelyx, Inc. faces several risks, primarily related to the outcomes of its clinical trials. If the results do not meet regulatory expectations, it could hinder product approvals and market entry.

What are the key factors to evaluate for ARDX?

Ardelyx, Inc. (ARDX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend yield as the company reinvests earnings into product development and clinical trials. Not financial advice.

How frequently does ARDX data refresh on this page?

ARDX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ARDX's recent stock price performance?

Ardelyx, Inc. (ARDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline addressing significant unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ARDX overvalued or undervalued right now?

Ardelyx, Inc. (ARDX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 13 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.